Lecigon (Entacapone, Levodopa, Carbidopa Monohydrate)

Lecigon, a fixed‑dose combination of levodopa, carbidopa, and entacapone, is employed in the treatment of Parkinson’s disease, a neurodegenerative disorder affecting dopamine pathways.

• Parkinson’s disease (motor fluctuations): Improves control of tremor, rigidity, and bradykinesia during periods when levodopa alone becomes less effective.
• Parkinson’s disease (early stage): Enhances the initial therapeutic response to levodopa, reducing the need for dose escalation.
• Parkinson’s disease (advanced): Decreases daily “off” time and supports more consistent motor performance throughout the day.

• Levodopa crosses the blood‑brain barrier and is decarboxylated to dopamine, replenishing deficient central dopamine in Parkinson’s disease. Carbidopa inhibits peripheral aromatic L‑amino‑acid decarboxylase, preventing premature conversion of levodopa and reducing peripheral side effects. Entacapone blocks catechol‑O‑methyltransferase (COMT), slowing levodopa metabolism and extending its plasma half‑life, thereby providing more stable dopaminergic stimulation.

Lecigon may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Dizziness: sensation of light‑headedness, especially on standing.
• Headache: transient cranial discomfort.
• Orthostatic hypotension: drop in blood pressure upon standing.
• Insomnia: difficulty initiating or maintaining sleep.
• Dyskinesia: involuntary movements, often dose‑related.

Serious or Rare Side Effects

• Severe hypotension: marked blood pressure decline requiring medical attention.
• Hepatic dysfunction: abnormal liver enzymes or hepatitis.
• Hallucinations or psychosis: visual or auditory disturbances.
• Neuroleptic malignant syndrome: rare life‑threatening reaction with fever and rigidity.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Severe dyskinesia: disabling involuntary movements.

When prescribing or dispensing Lecigon, several safety considerations should be observed.

• Monitor blood pressure: watch for orthostatic hypotension, especially in elderly patients.
• Assess liver function: entacapone may affect hepatic enzymes; periodic testing is advised.
• Evaluate psychiatric status: hallucinations or confusion can emerge, requiring dose adjustment.
• Avoid abrupt discontinuation: sudden cessation may worsen Parkinsonian symptoms.
• Use with caution in patients with cardiovascular disease: potential for arrhythmias.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Lecigon can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis.
• Anticholinergic agents (e.g., benztropine): may diminish levodopa’s therapeutic effect.
• Antihypertensive drugs: additive hypotensive effect leading to severe blood pressure drop.
• Iron or calcium supplements taken simultaneously: reduce levodopa absorption.

Moderate Interactions (Monitor Closely)

• Selective serotonin reuptake inhibitors (SSRIs): possible increase in serotonin syndrome risk.
• Central nervous system depressants (e.g., benzodiazepines): may enhance dizziness and sedation.
• High‑protein meals: can compete with levodopa transport, decreasing its bioavailability.